{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060049","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.521698+00:00","generated_at":"2026-06-02T00:03:19.384320+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aspira Q1 revenue $2.2M; OvaWatch volume up 114% YoY","bullets":["Product revenue $2.2M, down 4% YoY; OvaSuite volume 5,829 units (-7%).","Gross profit margin improved to 56% from 51% in Q1 2023.","Cash used in operating activities $4.4M, down 22% YoY; 2024 target stays $15-18M.","OvaWatch volume grew 114% YoY; longitudinal monitoring feature launched.","New Anthem Blue Cross CA coverage agreement for OvaSuite effective June 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060049","json":"https://secwatch.observer/filing/0000950170-24-060049.json","markdown":"https://secwatch.observer/filing/0000950170-24-060049.md","text":"https://secwatch.observer/filing/0000950170-24-060049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000095017024060049/0000950170-24-060049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000095017024060049/awh-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:03:19.384320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e8850eb593c9f48fc0dab54c5a823895422e231","claim":"Aspira Women's Health Inc. reported first quarter ended March 31, 2024 results: revenue $2.2 million. Guidance reaffirmed.","evidence_excerpt":"by reference language in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Aspira Women’s Health Reports First Quarter 2024 Financial Results Q1 2024 OvaSuite SM revenue of $2.2 million and volume of 5,829 units Q1 2024 cash utilization of $4.4 million, a decrease of 22% compared to Q1 2023 Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000095017024060049/0000950170-24-060049-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$2.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}